Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenges associated with synthetic lethality in cancer therapeutics, including the development of reliable predictive biomarkers of response and resistance, and identification of which patients will benefit or not benefit from these treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.